Welcome to Protein Degradation & Targeting Undruggables Congress Europe
Join leading experts & researchers from pharma, biotech and academic research institutions at the most established European event for undruggable drug discovery.
Across two comprehensive days, deep dive sessions allow you to explore cutting-edge advancements in targeted protein degradation, address challenges in discovering ligases & ligands, ensure safety of PROTACs and leverage induced proximity concepts. With more opportunities to build partnerships than ever before through roundtables, workshops and 1-2-1 meeting opportunities, it provides an unmissable chance to optimize your research outcomes, pipeline viability and therapeutic success across diverse indications.
Meet the speakers
Andreas Reichel
Gwenn Hansen
Brad Enerson
Luc Brunsveld
Manfred Koegl
Manfred Koegl is a director in Oncology Research in Vienna, working on the discovery and implementation of new therapeutic concepts in cancer. Presently, his team focuses on targeted protein degradation in cancer cell signaling.
Before 2010, he worked at the German Cancer Research Center in Heidelberg, Germany. He has worked at several small biotech companies in Heidelberg, including Phenex Pharmaceuticals. Manfred Koegl studied biology in Vienna and received his PhD in cell biology in 1994 at the EMBL, Heidelberg.
Greg Hollingworth
Kevin Moreau
Mary Matyskiela
Ted Suh
Alzbeta Tuerkova
Hyunsun Jo
Dr. Hyunsun Jo is an entrepreneur in the biopharmaceutical industry. He is currently a Founder and Chief Executive Officer at Pin Therapeutics, which is located in South San Francisco and South Korea. Pin Therapeutics is backed by many venture capitals in South Korea and actively developing integrative drug discovery platform at the field of protein degradation therapeutics using small molecules. Prior to founding Pin Therapeutics, Dr. Jo has founded two biotech companies called by a LabQnA and an Embedbio. He obtained his BA and PhD in Molecular Biology (Metabolic Diseases) at Seoul National University and Postdoc (aging-related diseases) at the Gladstone Institute (UCSF).
Giovanni Spagnolli
Matthias Brand
Ryoma Hara
Marcus Hartmann
Merve Mutlu
Martin Hemmerling
Jacob Aguirre
Benedict Cross
Fiona Sorrell
Konstantinos Tzelepis
Dennis Gillingham
Axel Vicart
Caroline Rynn
Steven Edenson
Ingrid Wertz
Katelyn Cassidy
Thomas Geiger
Renato Alves
Patrick Gunning
Magnus Walter
Kwok Ho Chan
Malik Muller
Axel Vicart
Katelyn Cassidy
Download the 2023 programme
View the full event programme for the Protein Degradation & Targeting Undruggables Congress Europe 2023!
What's new this year?
1) Improved Networking Opportunities
Meet your next collaborator, with a revamped programme allowing for more business-critical partnering opportunities than ever with over 8 hours of dedicated networking time
2) More Key Players
Meet the game changers from across the industry, with new companies confirmed for 2023 including Dunad, Nurix, Kymera, Abagon, Neomorph and C4 Therapeutics.
3) Business Strategy Sessions
In a market still in its infancy, its critical to gain the strategic insights you need to ensure your business thrives – and we’re bringing together the late-stage companies paving the way in Europe for Protein Degradation to share their guidance on running a robust biotech.
Download the agenda
Who will you meet?
Attendee Testimonials
Delegate Packages
Sending Your Team? Group Discounts Available!
Applicable for Primary Market, Service Provider and Industry Rates Only. Not available for Academic or ‘Start-Up’ rates
Book a Team of 3+ - Save an Additional 10% Off
Book a Team of 5+ - Save an Additional 15% Off
If you would like to register a team of 3 or more, please email [email protected] for your discount coupon code before registering. PLEASE NOTE: Discounts cannot be combined with Early Bird Pricing or any other discount or offer. If you have any questions about your registration, please call us on +44 (0)20 3696 2920
Ticket price will increase after
— January 1, 1970 —
Become a partner
Protein Degradation & Targeting Undruggables is your global, multi-channel partner to reach, engage and interact with the most influential and important stakeholders in the world of protein degradation. With a solution to hit every objective, our high-level programmes, tailored introductions, bespoke networking and content-driven marketing offer multiple ways to engage your target market both at the event and in the run up.
Why partner with us?
⦁ Be recognized as an industry leader
⦁ Get the eyes of hundreds of decision makers on your brand
⦁ Create space for the most important conversations, and the ones you never knew were out there
⦁ Network with the protein degradation industry elite
⦁ Amplify your biggest announcements, research and expertise
Want to know more? We’re here to help you find out all about partnership options including:
Thought Leadership: Presentations, Panel Discussions, Roundtables, Workshops
Networking: 1-1 Meetings, Breakfast Briefings, Networking Dinners, Drinks Party
Brand Awareness: Track Sponsorship, Keynote Presentation, Networking Booth
Find out more by calling us at +44 (0)20 3696 2920 or email Jack Tollervey at [email protected]
Protein Degradation Media Kit
For more information on webinars, roundtables, content marketing packages, interviews and bespoke opportunities to accelerate Protein dedgradation innovation, download the Media Kit below.
If you have any questions, please contact JackTollervey, Commercial Partnerships Manager, [email protected].
2023 Partners
Platinum Sponsor
Pelago Bioscience AB
Website: https://www.pelagobio.com/
Pelago Bioscience AB established in 2013 provides and develops the patented Cellular Thermal Shift Assay (CETSA®) for use in determination and quantification of drug–target interactions, to accelerate drug discovery and diagnostics development. CETSA® provides a quantitative measure of target engagement and the biophysical readout of affinity, and adds real value to existing efficacy assays. We deliver complete target engagement hit confirmation data sets, develop and validate assays for use in screening cascades, and profile candidate drugs based on the CETSA® method, tailored to the project need.
Promega
Website: https://www.promega.com
Promega is committed to excellence in technologies and compound profiling services to assess key processes in Targeted Protein Degradation and Induced Proximity mechanisms. From assessing protein degradation in real time, to understanding compound binding and permeability, to ternary complex formation and more. Our CRIPSR HiBiT content covers hundreds of pre-built targets. Novel software analysis tools allow for the determination of target protein degradation rates, DC50 potency values, recovery profiles and more.
Silver Sponsors
Event Partner
Jubilant Biosys
Website: https://www.jubilantbiosys.com/
Please visit our website for more information.Proteome Sciences
Website: https://www.proteomics.com/
Proteome Sciences is a Contract Research Organisation (CRO) specialising in the analysis of proteins detected by Mass Spectrometry. We offer various Discovery and Targeted Services to characterise proteins and their associated post translational modifications.
By using LC-MS2, LC-MS3, SysQuant® and TMTcalibratorTM methodologies on samples that originate from tissue to biological fluids, we can detect over 8,000 proteins per sample. With our proprietary bioinformatics software, these can be trimmed down to some tens of proteins that are either up-, or down-regulated in either disease progression or drug treatment.
Using our unique TMTpro isobaric mass tags, we can run up to 15 samples per single experiment thereby allowing relative protein quantification between samples. By using a reference channel, multiple experiments can be performed sequentially, thereby allowing 30 to 100+ samples to be characterized in one project. Sensitivity is equivalent to conventional ELISA in many cases.
In the clinical area, we offer single or multiplexed protein measurements on customer selected proteins either with or without a PTM. Proteins selected can be either known previously, or more often detected above via our Discovery Services. We can measure up to 100 multiplex proteins per sample in a GCLP accredited Targeted Mass Spectrometric assay using clinically relevant samples such as plasma and CSF. Again, sensitivity is equivalent to conventional ELISA in many cases.
Sygnature Discovery
Website: https://www.sygnaturediscovery.com/
Please visit our website for more information.Media Partners
Drug Discovery World
Website: https://www.ddw-online.com/
Drug Discovery World is the multi-platform global voice for the drug discovery community. From research stage to clinical trials the brand covers the scientific and commercial process involved in getting a drug to market–research, target identification and validation, drug molecule identification, lead molecule optimisation, pre-clinical research, clinical trial authorisation and application, and clinical trials phase I and II. DDW readers learn how to turn science into business.
DDW is available as a quarterly printed publication, online and as a free-to-download app containing trusted content as well as premium hand-picked intelligence for anyone involved in drug discovery and development. Readers can also sign up for our free weekly e-newsletter.
From bench through to boardroom DDW offers commercial insight for researchers, scientists and decision-makers involved in drug discovery and development. We cover the latest news and events in the global pharmaceutical, biopharmaceutical and biotech sectors, as well as the technology and processes to help create vaccines, therapeutics and drugs.
News Medical Lifesciences
Website: https://www.news-medical.net/
News-Medical is an online, open-access medical information provider for healthcare and life science professionals, medical researchers and engaged consumers. With visitors from over 200 countries, News-Medical is regarded as a world leader in the distribution of online medical and life science information.
In addition to sourcing and curating the latest daily medical news, News-Medical conducts and publishes interviews with experts in both academia and the healthcare industry through the Thought Leaders and Insights from Industry series. News-Medical also provide encyclopedic health articles, including featured pieces written by leading experts as part of the MediKnowledge series.
News-Medical is owned and operated by AZoM.com Limited trading as AZoNetwork, a specialist online publisher of science and engineering websites based in the UK and Australia.
pharmaphorum
Website: https://pharmaphorum.com/
pharmaphorum is a content and communications company offering a unique hybrid of publisher and agency working in pharma and healthcare.
pharmaphorum.com is our own independent flagship publication. It serves over 3 million unique users annually and its news and information is widely recognised as a leading source of thought leadership and strategic content for pharmaceutical professionals all over the world.
Our innovative digital magazine Deep Dive provides cutting edge insight on pharma industry trends to an audience of 100K per issue.
Select Science
Website: https://www.selectscience.net/
Please visit our website for more information.World Pharma Today
Website: https://www.worldpharmatoday.com/
Please visit our website for more information.
Highlights from previous years
About Kisaco Research
Kisaco Research produces, designs and hosts B2B industry conferences, exhibitions and communities – focused on a specialized selection of topic areas.
Meet industry peers that will help build a career-changing network for life.
Learn from the mistakes of your peers as much as their successes—ambitious industry stalwarts who are happy to share not just what has made them successful so far but also their plans for future proofing their companies.
Note down the inspired insight that will form the foundation for future strategies and roadmaps, both at our events and through our online communities.
Invest both in your company growth and your own personal development by signing up to one of our events and get started.